Trial Search Results

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Palonosetron
  • Drug: Hydroxyzine
  • Other: Placebo

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Healthy males

   - Ages 18-35

   - No allergies to morphine or palonosetron

   - No history of addiction or substance abuse

Exclusion Criteria:

   - Female

   - Younger than 18 or older than 35

   - History of substance abuse

   - Raynaud's disease or coronary artery disease

   - Allergies to morphine or palonosetron

Ages Eligible for Study

18 Years - 35 Years

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting